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Tissue plasminogen activator purified from human uterine tissue exhibits differences in N-terminal starting 
positions in relation to the melanoma cell plasminogen activator usually studied. A new starting position 
is compatible with an additional N-terminal processing apart from those already known. Like the 
melanoma activator, the uterine activator was found to yield protein chains starting at either of two 
positions. Gne of these was identical between uterine and melanoma activators, whereas the other was 
unique m each case. The most abundant startmg positron for the uterine preparation was at a vahne 
residue, apparently from cleavage of a Gln-Val bond, and corresponding to Val-7 of the longest form of 
the melanoma activator chain. 
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1. INTRODUCTION 
The structure of tissue plasminogen activator (t- 
PA) has recently been extensively studied. 
Bacterial clones containing activator cDNA se- 
quences have been isolated [ 1,2] and an amino acid 
sequence of 527 residues was deduced, with serine 
as the suggested N-terminal amino acid [l]. Struc- 
tural studies of the purified protein from the 
melanoma cell line confirmed the structure de- 
duced [3] but also showed the presence of 4 dif- 
ferent heterogeneities [4-61. 
If purified under the protection of a protease in- 
hibitor (aprotinin), the product obtained was a 
single-chain polypeptide [7,8] which was found to 
be heterogeneous in the N-terminus. About 50% 
of the molecules were 3 residues longer (L-chains) 
than the rest (S-chains) [6]. This heterogeneity was 
apparently associated with a Ser/Gly microhetero- 
Abbreviation: t-PA, tissue-type plasmmogen activator 
geneity in position L-4 (equal to S-l). Treatment of 
the single-chain activator with plasmin causes 
cleavage of the polypeptide approximately in the 
middle to give two disulfide connected chains (A 
and B) from the N- and C-terminal parts, respec- 
tively [4]. In addition, plasmin also cleaves off the 
differential tripeptide of the original N-terminal 
part, thus removing the S/L difference. Finally, 
two variants of tissue plasminogen activator can be 
separated on arginine-Sepharose (variant I and II 
in order of elution), having different mobilities on 
SDS-polyacrylamide gel electrophoresis. Their 
size difference resides in the A-chain [5]. All these 
data from t-PA have been derived from products 
of a melanoma cell line (Bowes). 
We have studied here the N-terminal sequences 
of single-chain and two-chain preparations of 
human uterine tissue plasminogen activator. The 
uterine activator was recovered in still another dif- 
ferent form from those known before for t-PA, 
suggesting one further differential proteolysis in 
the N-terminal region. 
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2. MATERIALS AND METHODS 
Human uterine t-PA was isolated from uteri ob- 
tained at autopsy. Purification was performed 
essentially as in [8] with the only difference being 
the use of Tween 80 (0.1 g/l) instead of Triton 
X-100. The preparations usually gave a mixture of 
single-chain and two-chain molecules even when 
aprotinin was present during purification. One 
preparation, however, was essentially single-chain 
t-PA and was selected for N-terminal sequence 
analysis together with a preparation containing a 
mixture of both forms. The latter preparation is 
denoted two-chain form here. 
material corresponding to the radioactive protein 
peak was pooled (7 ml), concentrated under a 
stream of nitrogen to 600~1 and applied for 
degradation in a liquid phase Beckman 890D se- 
quencer . Phenylthiohydantoins were identified 
and quantitated using reverse-phase high- 
performance liquid chromatography (Hewlett 
Packard 1084B) with an acetonitrile gradient 
system [9]. 
3. RESULTS 
For reduction and Scarboxymethylation, the 
purified enzyme (about 2OOpg of single-chain ac- 
tivator and 1300 pg of the two chain form) was 
dissolved in 400 pl of 1.4 M Tris-HCI @H 8.3) 
and 200~1 of 0.8% SDS. Dithiothreitol (10~1, 
500 mM) was added and, after incubation under 
nitrogen at 37°C for 2.5 h, also 150~1 of 100 mM 
iodo[2-14C]acetate (24 pCi). Alkylation was al- 
lowed to proceed for 1.5 h at 37°C and was stop- 
ped by the addition of 20 ~1 2-mercaptoethanol. 
The product was desalted on a Sephadex G-25 col- 
umn (0.5 x 66 cm) equilibrated in 0.1% SDS. The 
Results from sequence analyses of single- and 
two-chain activator preparations are shown in 
table 1. The single-chain material gave two amino 
acid sequences in different yield, with a main struc- 
ture having valine as the N-terminal amino acid. 
The amino acid sequence showed that this residue 
corresponds to valine in position 7 of the ‘long’ (L- 
chain [6]) single-chain melanoma t-PA. The other 
structure, constituting about 30% of the 
molecules, had serine as the N-terminal residue, 
corresponding to position 4 in the t-PA L-chain 
structure (equivalent o position 1 of the S-chain 
[a]). Relationships between the uterine t-PA struc- 
ture (U) now determined and the melanoma ac- 
Table 1 
Results of sequence analyses of single- and two-chain preparations of uterine ttssue plasmmogen activator 
Cycle Single-chain activator 
Residue identified 
Two-chain activator 
Residue identified 
A-chain B-chain 
1 Val( 1.7)/Ser Val(lS.6)Der Ile(15.4) 
2 Ile(2.O)/Tyr(0.6) Ile(16.1)/Tyr(3.2) Lys(7.3) Leu(7.7) 
3 Cys(Cm)/Glx Cys(Cm)/Glx Gly 
4 - Nal(O.5) ArgNal(4.8) Gl Y Val(8.9) 
5 Asp/Ile(0.7) Asp/Ile(3.6) Leu(17.0) Ala(6.6) 
6 Glu Glu Phe(13.4) 
7 Lys(O.7) Lys(6.9) Ala( 16.7) Leu(S.0) 
8 Thr Thr Asp 
9 Glx Gln Ile(13.0) 
10 Met(0.8) Met(3.8) Ala(12.6) 
Values show nmol recovered of stable PTH-derivatives from applications of 3 nmol (single-chain preparation) and 
20 nmol (two-chain preparation) of polypeptide. As shown, the single-chain preparation gave two sequences m different 
yield (relative yield 3 : l), whereas 3 structures were identified in the two-chain preparation (relative yield 5 : 1: 5). In 
some positions, residues corresponding to a fourth structure were also Identified (last column). Valine in cycle 4 (with 
a sum of 13 7 nmol) is present in two structures and listed wrth separate recoveries in the same relative ratio as Be/Ala 
m cycle 5 
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L S U B ,I 2 a,4 5 6,7 8 9 10 11 12 If 279 280 281 202 283 28b 285 286 281 28(1 510 
Gly-Ala-Arg-Ser-T~~r-Gln-Val-Ile-Cys-Arg-Asp-Glu-Lys-........ ~I1e-Lys-Gly-Gly-Leu-Phe-Ala-Asp-I1e-Ala-...C-terminus 
I L-chain , 
I S-chain I 
U-chain I 
I A-chain B-chain I 
Fig.1. Summary of all characterized cleavage sites in tissue plasminogen activator. L and S are cleavage sites found in 
single-chain melanoma ctivator preparations [4,6] and U denotes the new cleavage site found in both single- and two- 
chain preparations of the uterine activator (here). B-cleavage converts the single-chain molecule into a two-chain form. 
Numbers are from [ll after adjustment according to the results of [6]. 
tivator structures (L and S) previously reported are 
shown in fig.1. The two-chain uterine activator 
revealed the same two sequences as the single-chain 
form (about 80% of the non-B-chains had Val as 
N-terminal residue) together with a third amino 
acid sequence, which was identified as the N- 
terminal region of the B-chain. 
These data show the occurrence of a new and 
previously unknown cleavage in the N-terminal 
part of human t-PA. In addition, the cleavage in 
the middle of the molecule producing the A- and 
B-chains (B-cleavage) is shown to be identical for 
two-chain uterine activator and plasmin-treated 
melanoma activator. A summary of cleavage sites 
discovered in different t-PA preparations is shown 
in table 2 and further outlined in fig. 1. It may be 
added that for the two-chain preparation low but 
significant amounts of residues not matching any 
Table 2 
Summary of all reported cleavage sites and proteolytic 
processings of tissue plasminogen activator (t-PA) 
L S U B 
Single-chain melanoma t-PA + + - - 
Two-chain melanoma t-PA - + - + 
Single-chain uterine t-PA - + + - 
Two-chain uterine t-PA - (+) + + 
Parentheses indicate cleavage in low yield (i.e., less than 
25% of major cleavage site(s)). Sites L, S, U and B are 
shown in fig.1 
of the sequences derived from cleavages at L, S, U 
or B sites (fig. 1) were also recovered (table 1): cycle 
2 (Leu), 5 (Ala), 7 (Leu) and possibly 4 (Val, which 
was recovered in higher yield than expected from 
the A-chain alone, cf. table 1). Since this structure 
does not correspond to other regions of t-PA 
either, it probably reflects a contaminating peptide 
present in the two-chain preparation. 
4. DISCUSSION 
Analyses of t-PA preparations from human 
uterine tissue and melanoma cells have previously 
demonstrated a high degree of general similarity in 
amino acid composition, fibrin binding and im- 
munoreactivity [7]. Our results now demonstrate a
new cleavage in single-chain uterine t-PA, sug- 
gesting an additional processing, different from 
those known before. Noticeably, the cleavage oc- 
curs even in the absence of the B-cleavage that pro- 
duces the two-chain form, because Val-7 is also the 
major N-terminus of single-chain preparations. 
The new cleavage is therefore probably not caused 
by plasmin but still appears to be surprisingly 
specific. The protease causing this ‘U’-type 
cleavage is apparently not present or active in 
preparations from the melanoma cell cultures since 
no such cleavage has been demonstrated for the 
melanoma activator. 
Finally, in relation to different N-terminal pro- 
cessings, it may be noticed that a pattern with L- 
chains and 3 residues shorter S-chains similar to 
the t-PA pattern was found for the N-terminal part 
31 
Volume 168, number 1 FEBS LETTERS March 1984 
of high-M, urokinase [lo], and also that residues 6 
and 7 (Gln-Val) are identical for human t-PA and 
urokinase. It will be interesting to find out if these 
similarities are pure coincidence or if they reflect 
functional properties of plasminogen activators, 
and if the presently defined new cleavage may also 
occur in urokinase preparations. Regardless of 
functional possibilities, the N-terminal multiplicity 
of human t-PA is considerable (fig.1) and greater 
than previously anticipated. 
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